Brad Barnett
Chief Tech/Sci/R&D Officer chez COGENT BIOSCIENCES, INC.
Profil
Brad Barnett is currently the Chief Technology Officer at Cogent Biosciences, Inc. Prior to his current position, he worked at Array BioPharma, Inc. from 2000 to 2019, where he held the position of Vice President-Supply Chain & Manufacturing from 2015 to 2019.
Mr. Barnett received an undergraduate degree from Colorado State University and an MBA from The University of Colorado.
Postes actifs de Brad Barnett
| Sociétés | Poste | Début |
|---|---|---|
| COGENT BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Brad Barnett
| Sociétés | Poste | Fin |
|---|---|---|
| ARRAY TECHNOLOGIES, INC. | Corporate Officer/Principal | 01/08/2019 |
Formation de Brad Barnett
| Colorado State University | Undergraduate Degree |
| The University of Colorado | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| COGENT BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
